Evaluation of an Alternative Approach to Managing Diabetic Ketoacidosis: Combination Rapid-Acting and Basal Subcutaneous Insulin (CRABI-DKA)
Annals of Pharmacotherapy · 2026
DOI: 10.1177/10600280251331967 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Annals of Pharmacotherapy, 2026. Verfasst von Francisco Ibarra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Services, Community Regional Medical Center, Fresno, CA, USA. Hauptthemen laut MEDLINE: Diabetic Ketoacidosis, Hypoglycemic Agents, Insulin Lispro, Insulin Glargine. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Background
Although guidelines recognize the utility of subcutaneous (SQ) insulin regimens in the management of mild to moderate diabetic ketoacidosis (DKA), the need to administer SQ insulin every 1-2 hours may discourage their use due to frequent lab testing and admission to higher level of care units.
Objective
The purpose of this retrospective cohort study was to compare the proportion of patients whose mild to moderate DKA resolved within 12 hours after receiving the new SQ insulin order set and the institution’s intravenous (IV) insulin infusion order set.
Methods
The SQ order set included single doses of glargine (0.2 units/kg) and lispro (0.2 units/kg) upon therapy initiation, followed by lispro (0.1-0.2 units/kg) given every 3 hours until DKA resolution. The IV order set included a nurse-managed titratable infusion. Glucose and labs were checked every 3 hours in the SQ group, whereas glucose was checked hourly and labs were checked every 2 hours in the IV group. Patients were managed on units with a RN to patient ratio of 1:4-5 and 1:2-3 in the SQ and IV groups, respectively.
Results
The percentage of patients whose DKA resolved within 12 hours was 78% in the IV group and 90% in the SQ group ( P = 0.1). The time to DKA resolution and rates of hypoglycemia and hypokalemia were comparable between the groups. Conclusion and Relevance: Our study highlights the utility of combining rapid-acting and basal SQ insulin in the management of DKA and adds to the limited literature evaluating this approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Services, Community Regional Medical Center, Fresno, CA, USA.
- Department of Emergency Medicine, University of California San Francisco at Fresno, Fresno, CA, USA.
ORCID-Profile: Francisco Ibarra
Zitieren
APA
Ibarra, F., Cruz, M., Chinnock, B., Sunde, C., Campagne, D., & Uller, M. (2026). Evaluation of an Alternative Approach to Managing Diabetic Ketoacidosis: Combination Rapid-Acting and Basal Subcutaneous Insulin (CRABI-DKA). Annals of Pharmacotherapy. https://doi.org/10.1177/10600280251331967
Vancouver
Ibarra F, Cruz M, Chinnock B, Sunde C, Campagne D, Uller M. Evaluation of an Alternative Approach to Managing Diabetic Ketoacidosis: Combination Rapid-Acting and Basal Subcutaneous Insulin (CRABI-DKA). Annals of Pharmacotherapy. 2026. doi:10.1177/10600280251331967
BibTeX
@article{Ibarra2026,
author = {Ibarra, Francisco and Cruz, Mallory and Chinnock, Brian and Sunde, Caleb and Campagne, Danielle and Uller, Mia},
title = {Evaluation of an Alternative Approach to Managing Diabetic Ketoacidosis: Combination Rapid-Acting and Basal Subcutaneous Insulin (CRABI-DKA)},
journal = {Annals of Pharmacotherapy},
year = {2026},
doi = {10.1177/10600280251331967}
}
EUVIMED